Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HINT1 | P49773 | 3/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3278964 | 0.87 | KDM4E (0.48) | KDM4EPOLBHPGDHINT1F2 | |
| SCHEMBL3279870 | 0.83 | POLB (0.56) | KDM4EPOLBHPGDHINT1F2 | |
| SCHEMBL16359975 | 0.83 | POLB (0.56) | KDM4EPOLBHPGDHINT1F2 | |
| SCHEMBL3279868 | 0.83 | POLB (0.56) | KDM4EPOLBHPGDHINT1F2 | |
| SCHEMBL4579814 | 0.82 | POLB (0.56) | KDM4EPOLBHPGDHINT1P2RY2 | |
| SCHEMBL10446713 | 0.82 | POLB (0.56) | KDM4EPOLBHPGDHINT1P2RY2 | |
| SCHEMBL4579809 | 0.82 | POLB (0.56) | KDM4EPOLBHPGDHINT1P2RY2 | |
| SCHEMBL26476188 | 0.82 | KDM4E (0.54) | KDM4EPOLBHPGDHINT1F2 | |
| SCHEMBL31098063 | 0.82 | KDM4E (0.58) | KDM4EPOLBHPGDHINT1F2 | |
| SCHEMBL16987245 | 0.82 | ADA (0.48) | POLBSTING1PDE3AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414790-B2 | Exocyclic nitrogen atom protected nucleoside and method for producing and using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2019-09-17 | — | — | US | disclosed |
| US-20150225442-A1 | EXOCYLIC NITROGEN ATOM PROTECTED NUCLEOSIDE AND METHOD FOR PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414790-B2 | Exocyclic nitrogen atom protected nucleoside and method for producing and using the same | NT5C3B, RNGTT, UMPS | KDM4E 3251/4885POLB 66/4885HPGD 4241/4885 |
| US-20150225442-A1 | EXOCYLIC NITROGEN ATOM PROTECTED NUCLEOSIDE AND METHOD FOR PRODUCING AND USING THE SAME | NSUN2, RNGTT, NT5C3B | KDM4E 3686/4885POLB 231/4885HPGD 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.